Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
8.67
+0.17 (2.00%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Seres Therapeutics Revenue
In the year 2025, Seres Therapeutics had annual revenue of $789.00K. Seres Therapeutics had revenue of $438.00K in the quarter ending December 31, 2025.
Revenue (ttm)
$789.00K
Revenue Growth
n/a
P/S Ratio
105.34
Revenue / Employee
$11,955
Employees
66
Market Cap
83.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 789.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
| Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
| Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
| Dec 31, 2018 | 28.27M | -3.83M | -11.94% |
| Dec 31, 2017 | 32.10M | 10.33M | 47.48% |
| Dec 31, 2016 | 21.77M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 57.95M |
| NeurAxis | 3.57M |
| Kazia Therapeutics | 1.20M |
| Spruce Biosciences | 697.00K |
| aTyr Pharma | 190.00K |
| Impact BioMedical | 32.00K |
MCRB News
- 12 days ago - Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 20 days ago - Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript - Seeking Alpha
- 21 days ago - Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates - GlobeNewsWire
- 5 weeks ago - Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash - Benzinga
- 5 weeks ago - Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases - GlobeNewsWire
- 2 months ago - Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy - GlobeNewsWire
- 4 months ago - Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - GlobeNewsWire
- 4 months ago - Seres Therapeutics, Inc. (MCRB) Q3 2025 Earnings Call Transcript - Seeking Alpha